

Centrose Receives Federal Funding for Drug Discovery Engine

MADISON, WI. November 20, 2007 – A revolutionary drug development engine that enhances drugs by specifically adding novel sugars will now benefit from \$150,000 of additional funding. Centrose and the University of Wisconsin received notice that the National Science Foundation (NSF) will fund a joint effort aimed at optimizing a proprietary drug discovery method. Specifically, Centrose will use the funds to expand the sugar chemistry while the University will use their share to optimize the biochemistry behind the sugar attachment process.

To date, the platform has led to the discovery of a number of drugs having the potential to fight some of the most problematic diseases. Dr. Thorson a UW professor and founder of Centrose, says that the funds will allow him to further understand how Nature's processes of adding sugars to biological molecules work. At the same time, Centrose will work to exploit the chemistry needed to discover new therapies used fight cancer and drug resistance. "The ability to further accelerate and simplify this revolutionary sugar attachment process will radically enhance the global impact of our discovery", says Dr. Thorson.

Earlier this year, Centrose exclusively licensed a set of drug enhancement technologies from the Wisconsin Alumni Research Foundation (WARF) that use sugars to lower toxic effects and increase drug potency. Since then, the Company has raised over \$1 Million in private funding and received another \$500,000 in federal funding in the form of grants. The monies have allowed Centrose to further its cancer and antibiotic discovery programs. With this NSF funding, the Company now has funds to further its core discovery engine. "The NSF has viewed our technology platform as having broad applicability", states Dr. James Prudent the Company's Chief Executive Officer. "It's now our job to show that we can develop it to a level where the drugs of the future can be quickly constructed".

It is becoming increasingly clear that sugars play key roles in human health and disease. Sugars play such an important role in biology that experts tend to agree that the possibilities for sugar-based drugs seem to be absolutely endless. Therefore, it is not surprising that the sugar enhancement platform owned by WARF and exclusively licensed to Centrose continues to catch the eye of federal agencies. This is the third federal agency to fund the Company's efforts this year. Centrose expects positive results for all their federally funded programs and in a year's time, anticipates applying for follow on Phase II funding.

About Centrose LLC

Centrose, a Madison, Wis.-based biopharmaceutical company, is applying scientific breakthroughs in sugar chemistry to the discovery, development and commercialization of small molecule therapeutics. Centrose delivers commercially relevant technology for the attachment of any sugar molecule to any compound. Sugars are critical to the regulation of biological processes and pathways in the human body, and play fundamental roles in drug action. Several small-molecule drugs like erythromycin (a commonly used antibiotic) or doxorubicin (a commonly used anticancer) contain sugar linkages. It is the sugar linkages that bestow drug activity. Modifying existing small-molecule drugs with sugars have been shown to improve drug activity. Centrose's proprietary sugar technology enables the rapid enhancement of a wide variety of important drugs in a one step process with manufacturing scalability. Centrose owns a broad set of patents and patent applications issued and filed by the Wisconsin Alumni Research Foundation and The Sloan Kettering Institute.

Contacts:

James Prudent, Ph.D.
Chief Executive Officer,
Centrose LLC
(608) 209-8933